NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Forecast, Price & News $0.39 -0.03 (-7.14%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.38▼$0.4350-Day Range$0.38▼$0.6852-Week Range$0.34▼$1.65Volume62,074 shsAverage Volume111,550 shsMarket Capitalization$11.63 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Moleculin Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,592.3% Upside$10.50 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector344th out of 968 stocksPharmaceutical Preparations Industry145th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Moleculin Biotech has a forecasted upside of 2,592.3% from its current price of $0.39.Amount of Analyst CoverageMoleculin Biotech has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Moleculin Biotech have been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 75.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 2.2 News and Social Media Coverage News SentimentMoleculin Biotech has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 1 article on an average week.Search Interest2 people have searched for MBRX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 7.67% of the stock of Moleculin Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($0.94) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Moleculin Biotech (NASDAQ:MBRX) StockMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Read More MBRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBRX Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comMoleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)September 18, 2023 | markets.businessinsider.comMoleculin Biotech Reports Independent Report Of No Cardiotoxicity In AnnamycinSeptember 23, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 18, 2023 | finance.yahoo.comMoleculin Announces New Positive Independent Report of No Cardiotoxicity in AnnamycinSeptember 18, 2023 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.comSeptember 15, 2023 | investorplace.comWhy Is Moleculin Biotech (MBRX) Stock Is Moving Today?September 14, 2023 | finance.yahoo.comMoleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingSeptember 5, 2023 | finance.yahoo.comMoleculin to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 23, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 12, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX)August 12, 2023 | finance.yahoo.comQ2 2023 Moleculin Biotech Inc Earnings CallAugust 11, 2023 | bizjournals.comHouston Biotech NewsAugust 11, 2023 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comMoleculin Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | benzinga.comEarnings Preview For Moleculin BiotechAugust 7, 2023 | finance.yahoo.comMoleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short SellingAugust 3, 2023 | finance.yahoo.comMoleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and WebcastJuly 13, 2023 | marketwatch.comMoleculin Biotech Shares Rise 17% on Trial's Safety Profile of AnnamycinJuly 13, 2023 | finance.yahoo.comMoleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)July 6, 2023 | finance.yahoo.comMoleculin to Participate in the Virtual Investor Summer Spotlight SeriesJune 13, 2023 | finance.yahoo.comMoleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestMay 30, 2023 | finance.yahoo.comMoleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023May 13, 2023 | msn.comMoleculin Biotech: Q1 Earnings InsightsMay 12, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Moleculin Biotech (MBRX)May 12, 2023 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comMoleculin Reports First Quarter 2023 Financial ResultsSee More Headlines Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Company Calendar Last Earnings8/11/2023Today9/23/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$16.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+2,592.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.57% Return on Assets-52.99% Debt Debt-to-Equity RatioN/A Current Ratio5.40 Quick Ratio5.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.21Miscellaneous Outstanding Shares29,810,000Free Float27,813,000Market Cap$11.63 million OptionableNot Optionable Beta1.97 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 63)Founder, Chairman, Pres & CEO Comp: $1.35MMr. Jonathan P. Foster CPA (Age 59)Exec. VP & CFO Comp: $653.69kDr. Donald H. Picker Ph.D. (Age 77)Chief Scientific Officer Comp: $520.84kDr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardDr. Robert C. Shepard FACP (Age 71)M.D., F.A.C.P., Chief Medical Officer of Annamycin Dr. John Paul Waymack M.D. (Age 71)Sc.D., Sr. Chief Medical Officer Dr. Sandra L. Silberman M.D. (Age 68)Ph.D., Chief Medical Officer of New Products Dr. Wolfram C. M. Dempke M.B.A.M.D., Ph.D., European Chief Medical OfficerMs. Jacqueline Northcut (Age 61)Consultant Mr. Louis Ploth Jr. (Age 69)Independent Advisor More ExecutivesKey CompetitorsLipella PharmaceuticalsNASDAQ:LIPOBiofronteraNASDAQ:BFRIVYNE TherapeuticsNASDAQ:VYNELandos BiopharmaNASDAQ:LABPAraviveNASDAQ:ARAVView All CompetitorsInsiders & InstitutionsBlackRock Inc.Sold 62,496 shares on 8/11/2023Ownership: 0.661%Renaissance Technologies LLCBought 32,795 shares on 8/11/2023Ownership: 0.429%Walter V KlempBought 45,000 shares on 11/25/2022Total: $57,600.00 ($1.28/share)Walter V KlempBought 22,500 shares on 11/21/2022Total: $25,875.00 ($1.15/share)Walter V KlempBought 85,213 shares on 11/16/2022Total: $82,656.61 ($0.97/share)View All Insider TransactionsView All Institutional Transactions MBRX Stock - Frequently Asked Questions Should I buy or sell Moleculin Biotech stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks. What is Moleculin Biotech's stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Moleculin Biotech's stock. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 2,592.3% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts. How have MBRX shares performed in 2023? Moleculin Biotech's stock was trading at $1.06 on January 1st, 2023. Since then, MBRX shares have decreased by 63.2% and is now trading at $0.39. View the best growth stocks for 2023 here. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 38,100 shares, a decrease of 75.4% from the August 15th total of 155,100 shares. Based on an average daily volume of 164,900 shares, the days-to-cover ratio is presently 0.2 days. View Moleculin Biotech's Short Interest. When is Moleculin Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our MBRX earnings forecast. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.08. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. When did Moleculin Biotech's stock split? Shares of Moleculin Biotech reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL). What is Moleculin Biotech's stock symbol? Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX." Who are Moleculin Biotech's major shareholders? Moleculin Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.66%) and Renaissance Technologies LLC (0.43%). View institutional ownership trends. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Moleculin Biotech's stock price today? One share of MBRX stock can currently be purchased for approximately $0.39. How much money does Moleculin Biotech make? Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $11.63 million. The company earns $-29,020,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. How can I contact Moleculin Biotech? Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com. This page (NASDAQ:MBRX) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.